Evaxion A/S (EVAX)
 NASDAQ: EVAX · Real-Time Price · USD
 5.77
 +0.02 (0.35%)
  At close: Nov 3, 2025, 4:00 PM EST
5.57
 -0.20 (-3.47%)
  Pre-market: Nov 4, 2025, 5:20 AM EST
Evaxion Revenue
Evaxion had revenue of $37.00K in the quarter ending June 30, 2025, a decrease of -75.97%. This brings the company's revenue in the last twelve months to $3.18M, up 1,042.45% year-over-year. In the year 2024, Evaxion had annual revenue of $3.34M with 4,480.82% growth.
Revenue (ttm) 
 $3.18M
Revenue Growth 
 +1,042.45%
P/S Ratio 
 4.89
Revenue / Employee 
 $69,043
Employees 
 46
Market Cap 
36.45M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 3.34M | 3.27M | 4,480.82% | 
| Dec 31, 2023 | 73.00K | - | - | 
| Dec 31, 2022 | - | - | - | 
| Dec 31, 2021 | - | - | - | 
| Dec 31, 2020 | - | - | - | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 64.24B | 
| AbbVie | 59.64B | 
| Eli Lilly and Company | 59.42B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Novo Nordisk | 49.11B | 
EVAX News
- 21 hours ago - Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate - GlobeNewsWire
 - 3 days ago - Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025 - GlobeNewsWire
 - 3 days ago - Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025 - GlobeNewsWire
 - 4 days ago - Evaxion raises $7.2 million, extending cash runway to second half of 2027 - GlobeNewsWire
 - 7 days ago - Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer - GlobeNewsWire
 - 12 days ago - Evaxion A/S (EVAX) Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma Transcript - Seeking Alpha
 - 17 days ago - Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01 - GlobeNewsWire
 - 21 days ago - Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 - GlobeNewsWire